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ORIGINAL RESEARCH
Ischemic Preconditioning Improves 
Microvascular Endothelial Function 
in Remote Vasculature by Enhanced 
Prostacyclin Production
Nicolai Rytter , MSc; Howard Carter, PhD; Peter Piil, PhD; Henrik Sørensen, MD, DMSc; Thomas Ehlers, MD; 
Frederik Holmegaard, MSc; Christoffer Tuxen, MSc; Helen Jones, PhD; Dick Thijssen, PhD;  
Lasse Gliemann , PhD; Ylva Hellsten , DMSc
BACKGROUND: The mechanisms underlying the effect of preconditioning on remote microvasculature remains undisclosed. The 
primary objective was to document the remote effect of ischemic preconditioning on microvascular function in humans. The 
secondary objective was to test if exercise also induces remote microvascular effects.
METHODS AND RESULTS: A total of 12 healthy young men and women participated in 2 experimental days in a random counter-
balanced order. On one day the participants underwent 4×5 minutes of forearm ischemic preconditioning, and on the other 
day they completed 4×5 minutes of hand-grip exercise. On both days, catheters were placed in the brachial and femoral 
artery and vein for infusion of acetylcholine, sodium nitroprusside, and epoprostenol. Vascular conductance was calculated 
from blood flow measurements with ultrasound Doppler and arterial and venous blood pressures. Ischemic preconditioning 
enhanced (P<0.05) the remote vasodilator response to intra-arterial acetylcholine in the leg at 5 and 90 minutes after applica-
tion. The enhanced response was associated with a 6-fold increase (P<0.05) in femoral venous plasma prostacyclin levels and 
with a transient increase (P<0.05) in arterial plasma levels of brain-derived neurotrophic factor and vascular endothelial growth 
factor. In contrast, hand-grip exercise did not influence remote microvascular function.
CONCLUSIONS: These findings demonstrate that ischemic preconditioning of the forearm improves remote microvascular en-
dothelial function and suggest that one of the underlying mechanisms is a humoral-mediated potentiation of prostacyclin 
formation.
Key Words: ischemic preconditioning ■ microvascular endothelial function ■ platelets ■ prostacyclin ■ vasodilation
Repeated bouts of ischemia followed by reperfu-sion, known as ischemic preconditioning, is a procedure that originally was shown to reduce 
myocardial infarct size in animals1 and subsequently 
also to protect against vascular injury.2 The protective 
effect was demonstrated to be remote, that is, effective 
also in organs not directly exposed to ischemia.3,4 In 
addition, ischemic preconditioning has been reported 
to induce improved vascular endothelial function of 
remote conduit arteries in human studies.5,6 These 
findings suggest a systemic vascular effect of ischemic 
preconditioning, which could be related to either neu-
ral or humoral signaling.7 Interestingly, a single session 
of exercise has recently also been shown to induce a 
remote cardioprotective effect,8,9 similar to that of isch-
emic preconditioning, but whether exercise can lead 
to improved remote microvascular function remains 
unclear.
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Although the abovementioned effects of remote 
ischemic preconditioning are likely to be of important 
clinical relevance,10,11 there are several critical aspects 
that remain to be resolved. First, it is unknown whether 
ischemic preconditioning improves not only macro-
vascular but also microvascular function, and thereby 
the control of vascular resistance. Second, the mech-
anism by which ischemic preconditioning induces its 
beneficial effects on the vasculature remains to be 
identified. Further knowledge of mechanisms would 
bring us closer to the development of a pharmaco-
logical intervention that can simulate or potentiate the 
effect. Third, it is unknown whether an acute exercise 
session can induce a beneficial effect on the remote 
microvasculature. This knowledge would provide fur-
ther insight into the mechanisms of preconditioning. 
In this study, we address these 3 aspects.
The observation that vascular protection can be 
transferred through blood from a preconditioned an-
imal to a naïve animal emphasizes that remote isch-
emic preconditioning is mediated through humoral 
signaling via plasma or cells such as platelets.12 
Platelets are likely candidates for conveying signal-
ing molecules to remote parts of the vasculature as 
they can take up and release compounds where 
needed.13,14 In animal studies, platelets have been 
found to carry and release serotonin, BDNF (brain-de-
rived neurotrophic factor) , and VEGF (vascular endo-
thelial growth factor), which are all compounds that 
can modulate vascular tone by promoting the forma-
tion of vasodilators, including prostacyclin, in vascu-
lar endothelium.15–19 Combined with our findings that 
prostacyclin is an important regulator of vascular tone 
in humans20,21 and with findings from animal models 
showing that acute ischemic preconditioning im-
proves endogenous formation of prostaglandins,22,23 
these data suggest that preconditioning could in part 
be mediated through this pathway.
The primary objective of the present study was to 
document the remote effect of ischemic preconditioning 
on microvascular endothelial function in humans as as-
sessed by vasodilatory responsiveness to intra-arterial 
acetylcholine. Moreover, we aimed to elucidate if en-
dogenous formation of prostacyclin was involved in the 
microvascular response to ischemic preconditioning. A 
secondary objective was to assess whether a remote 
microvascular effect could be achieved by exercise pre-
conditioning. We hypothesized that forearm ischemic 
preconditioning would improve remote microvascular 
function as determined in the leg and that this effect 
would be mediated via enhanced endogenous prosta-
cyclin formation. In addition, it was hypothesized that a 
session of hand-grip exercise would improve remote mi-
crovascular function.
METHODS
Because of the sensitive nature of the data collected for 
this study, requests to access the data set from quali-
fied researchers trained in human subject confidential-
ity protocols may be sent to the corresponding author.
Participants
A total of 12 healthy young participants (7 men, 5 
women) were included in the study (Table  S1). All 
participants were nonsmokers, showed no signs 
of cardiovascular diseases, and were not taking 
any chronic medications. The study was approved 
by the Ethics Committee of the Capital Region of 
Copenhagen (H-18000977), and all procedures were 
carried out in accordance with the latest guidelines 
of the Declaration of Helsinki. Written and oral in-
formed consent was obtained from all participants 
before final enrollment.
Experimental Design
Study Overview
The experimental design included 2 separate visits to 
the laboratory in randomized order, where the subjects 
CLINICAL PERSPECTIVE
What Is New?
• This is the first study to explore the acute effect 
of ischemic preconditioning on remote microcir-
culation in humans.
• We demonstrate that the vasodilator response 
to intra-arterial acetylcholine is enhanced in the 
leg after ischemic preconditioning applied at the 
arm.
• The enhanced vasodilatory responsiveness to 
acetylcholine in remote vascular tissue is asso-
ciated with increased prostacyclin production.
What Are the Clinical Implications?
• The findings suggest that ischemic precondi-
tioning may be an effective treatment strategy to 
improve remote microvascular endothelial func-
tion and endogenous prostacyclin production, 
which are essential steps in the prevention of 
cardiovascular morbidity and mortality.
Nonstandard Abbreviations and Acronyms
BDNF brain-derived neutrophic factor
6-keto PGF1α 6-keto prostaglandin F1α
VEGF vascular endothelial growth factor
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underwent either (1) ischemic preconditioning or (2) 
hand-grip exercise (Figure 1). Measurements of micro-
vascular function were conducted, and blood samples 
were drawn, simultaneously in 1 arm and 1 leg.
To address the primary aim (to elucidate whether 
ischemic preconditioning induces a remote effect 
on microvascular function), the vasodilator response 
to acetylcholine was determined in the leg at base-
line and after ischemic preconditioning of the arm. 
Measurements in the arm were conducted simulta-
neously to determine the local effect.
To explore the potential mechanisms underlying the 
effect of the intervention, plasma prostacyclin levels 
were determined in blood samples obtained before 
and after acetylcholine infusion given that acetylcho-
line stimulates prostacyclin formation.
To further evaluate mechanisms underlying 
changes in microvascular function, serotonin, BDNF, 
and VEGF were determined in platelets and plate-
let-free plasma obtained before and after ischemic 
conditioning. In addition, skeletal muscle biopsies 
were obtained from the leg to assess a potential in-
fluence of ischemic preconditioning on the expres-
sion of vascular proteins and to assess whether 
changes related to microvascular function occurred 
at the transcriptional level.
To address the secondary aim (to determine the 
effect of hand-grip exercise on remote microvascular 
function for comparison with that of the ischemic inter-
vention), the same experimental protocol as for isch-
emic preconditioning was conducted with hand-grip 
exercise.
Intervention
Participants were instructed to refrain from physi-
cal activity as well as caffeine and alcohol intake for 
24 hours before the experiments and to arrive in the 
laboratory at 8 am after a light breakfast (similar be-
tween visits).
The ischemic preconditioning protocol consisted of 
4 repetitive bouts of forearm occlusion, which were ac-
complished by rapidly inflating a pneumatic cuff (E20, 
D.E. Hokanson Inc., Bellevue, WA) to 220 mm Hg for 
5 minutes, followed by rapid deflation and 5 minutes of 
rest. The hand-grip exercise protocol was conducted as 4 
intermittent bouts, where participants performed 5 min-
utes of dynamic hand-grip exercise (SH5001, Saehan 
Corp., Masan, South Korea) with 30 contractions per 
minute, followed by 5 minutes of rest. The workload was 
based on the participants’ maximal voluntary isometric 
contraction and set to ensure that the participants were 
barely able to complete the 150 contractions in 1 bout. 
All sessions of ischemic preconditioning and hand-grip 
exercise were supervised by the same person, ensuring 
consistency between experiments.
Figure 1. Experimental protocol.
Vertical arrows refer to sampling of muscle biopsies for gene expression analysis (M), arterial blood for isolation of platelets and 
platelet-free plasma (B), and venous plasma for analysis of vasoactive compounds (P).
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Experimental Protocol
Under aseptic conditions and local anesthesia (li-
docaine, 20  mg  mL−1; Astra Zeneca, Cambridge, 
UK), catheters (20G, Arrow International, Reading, 
PA) were inserted in the femoral artery and vein 2 to 
4 cm below the inguinal ligament of the experimen-
tal leg. Under guidance of ultrasound, the tip of the 
catheter was placed in same position in the common 
femoral artery. A catheter was inserted in the brachial 
artery (20G, arterial cannula; Becton, Dickinson and 
Company, Sandy, UT) and in the basilic vein (18G, pe-
ripheral catheter; Becton, Dickinson and Company) 
of the experimental arm. A 3-way cock was placed 
on the arterial line so that infusions and blood pres-
sure measurements could be performed simultane-
ously. In the supine position with the experimental 
arm extended laterally, participants received simulta-
neous intra-arterial (brachial and femoral) infusion of 
acetylcholine (10 and 25 µg min−1 L tissue volume−1; 
miochol-E, Bausch & Lomb Inc., Bridgewater, NJ), 
sodium nitroprusside (3 µg min−1 L tissue volume−1; 
Hospira Inc., Lake Forest, IL), and epoprostenol 
(25 and 50 µg min−1 L tissue volume−1; Flolan, GSK 
Pharma, Brentford, UK).
On the first visit in the laboratory, leg and fore-
arm tissue volumes were estimated by anthropomet-
ric measures. The infusion doses were determined 
based on these measures. Infusions were separated 
by at least 15  minutes, and each dose was infused 
for ≈3 minutes. Measurements (blood flow and blood 
pressure) were performed in the last minute of respec-
tive infusion.
The entire infusion protocol was performed before 
(pre), 5  minutes after (post+5), and 90  minutes after 
(post+90) ischemic preconditioning or hand-grip exer-
cise (Figure 1).
Venous blood samples were collected at rest 
and during the highest dose of acetylcholine at pre 
and post+5. On the experimental day involving isch-
emic preconditioning, arterial blood for the isolation 
of platelets and platelet-free plasma was collected 
before (pre), in the arm immediately after (post arm) 
and in the leg 10 minutes after (post leg) the last cuff 
deflation.
In addition, skeletal muscle biopsies were obtained 
from the m. vastus lateralis before (pre) and 2.5 hours 
after (post) ischemic preconditioning (Figure 1).
Blood and Tissue Sampling
Venous Plasma
Venous blood was drawn in EDTA anticoagulated tubes 
and immediately centrifuged (5 minutes at 4000g and 
4°C), and aliquots of plasma were stored at −80°C until 
later analysis.
Platelets and Platelet-Free Plasma
Arterial blood was drawn in citrate-anticoagulated 
tubes and kept at room temperature until centrifuged 
(10 minutes at 200g and 20°C) to obtain platelet-rich 
plasma. The platelet-rich plasma was layered on top of 
a gradient density medium (iodixanol solution, OptiPrep, 
Sigma-Aldrich, St. Louis, MO) and centrifuged (15 min-
utes at 450g and 20°C), after which a fraction of 
isolated platelets and platelet-poor plasma was col-
lected. To obtain plasma completely free of platelets, 
the platelet-poor plasma was centrifuged (15 minutes 
at 450g and 20°C) once more on the density gradient 
medium, and a fraction of the plasma was collected as 
platelet-free plasma. In all collected samples, platelets 
were counted using a hematology analyzer (XP-300; 
Sysmex, Kobe, Japan). Isolated platelets were lysed in 
a fresh batch buffer (Meso Scale Diagnostics Tris lysis 
buffer, Meso Scale Diagnostics, Rockville, MD) on ice 
before being centrifuged (10 minutes at 10 000g and 
4°C), and the supernatant was kept as platelet lysate. 
All samples were stored at −80°C until later analysis.
Skeletal Muscle Biopsies
Under local anesthesia (lidocaine, 20 mg mL−1), skel-
etal muscle biopsies were obtained using the percu-
taneous needle biopsy technique with suction.24 The 
biopsies were immediately frozen in liquid nitrogen and 
stored at −80°C until further analysis.
Measurements
Hemodynamics
Arterial blood flow (leg, femoral arterial blood flow; 
forearm, brachial arterial blood flow) was measured 
with ultrasound Doppler (Vivid E9, GE Healthcare, 
Chicago, IL) equipped with a linear probe (L9) operat-
ing at an imaging frequency of 4/8 MHz and a Doppler 
frequency of 4.2 MHz. In the femoral artery, the site of 
measurement was distal to the inguinal ligament but 
above the bifurcation into the superficial and profound 
femoral branch to avoid turbulence from the bifurca-
tion. For measurements of brachial arterial flow, the 
probe was positioned approximately half way up the 
upper arm. All recordings were obtained at the low-
est possible insonation angle but always below 60°. 
Sample volume was maximized by choosing the wid-
est section of the artery, and recordings were made 
without interference of the vascular wall. A low-velocity 
filter (<1.8 m s−1) rejected noise caused by turbulence 
at the vascular wall. Doppler traces and B-mode im-
ages were recorded continuously and averaged over 
≈30 seconds. Arterial diameter was assessed during 
systole from B-mode images for each Doppler re-
cording. Intra-arterial and venous blood pressure and 
heart rate were monitored with transducers (Pressure 
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Monitoring Set, Edwards Lifesciences, Irvine, CA) po-
sitioned at the level of the heart. Vascular conduct-
ance was calculated by use of the following formula:
Vasoactive Compounds in Venous Plasma
Plasma levels of the stable metabolite of prostacyclin, 
6-keto prostaglandin F1α (PGF1α), and norepinephrine 
were measured with enzyme immunoassay kits (6-
keto PGF1α, Cayman Chemical Co., Ann Arbor, MI; nor-
epinephrine; LDN, Nordhorn, Germany) in accordance 
with the manufacturer’s instructions.
Serotonin, VEGF, and BDNF in Platelets and 
Platelet-Free Plasma
The content of serotonin in platelets and platelet-free 
plasma was measured with an enzyme immunoassay 
kit (IBL International, Hamburg, Germany) in accord-
ance with the manufacturer’s instructions, and VEGF 
and BDNF content were measured with an electro-
chemiluminescent assay kit (U-PLEX platform, Meso 
Scale Diagnostics).
Gene Expressions in Skeletal Muscle Biopsies
Total RNA was isolated from the muscle biopsies using 
a TRIzol reagent (Invitrogen, Carlsbad, CA) in accord-
ance with the manufacturer’s instructions. First-strand 
cDNA was synthesized from 1  μg of total RNA by 
SuperScript II reverse transcriptase (Invitrogen) as de-
scribed previously.25 The mRNA content of cyclooxy-
genase 1 (Hs00377726_m1), prostacyclin synthase 
(Hs00153133_m1), and endothelial NO synthase 
(Hs00167166_m1) was determined by real-time re-
verse transcription polymerase chain reaction (ABI 
PRISM 7900 Sequence Detection System, Applied 
Biosystems, Foster City, CA). The cDNAs were ampli-
fied using the TaqMan gene expression assays from 
Applied Biosystems. For each sample, the amount of 
target gene mRNA was normalized to GAPDH mRNA 
content. The effect of the interventions on the level of 
GAPDH mRNA was determined statistically, and no sig-
nificant effect was found with ischemic preconditioning.
Statistical Analysis
A priori sample size determination was performed based 
on previous data for the primary outcome, the difference 
in vasodilatory responsiveness to intra-arterial acetyl-
choline with ischemic preconditioning.26 Significance 
level was set to P<0.05 at a power level of 0.8. To detect 
a significant difference of 5.0±5.0 mL min−1 mm Hg−1 in 
vascular conductance with acetylcholine infusion, 12 
participants were needed. Statistical analyses were per-
formed with R (version 3.4.1, R Foundation for Statistical 
Computing, Vienna, Austria) using the interface RStudio 
(version 1.1.463, RStudio Team, Boston, MA).
To estimate limb and intervention-specific differ-
ences in the vasodilator response to intra-arterial in-
fusions, a linear mixed model approach27 was used 
with “time” (pre, post+5, post+90) and “infusion dose” 
(dose1, dose2) as fixed factors. Likewise, a linear mixed 
model was used for differences in baseline hemody-
namics, venous plasma norepinephrine, and 6-keto 
PGF1α levels and platelet and platelet-free plasma levels 
of serotonin, VEGF, and BDNF with “time” (pre, post+5, 
post+90) as the fixed factor. For all analysis, partici-
pants were specified as a repeated factor and identifier 
of random variation. Model checking as well as homo-
geneity of variance and normal distribution were con-
firmed through residual and Q-Q plots. To control for 
type I error regarding multiple statistical testing on the 
response to intra-arterial infusions and venous plasma 
prostacyclin levels, a Bonferroni correction was applied 
within the family of statistical tests by multiplying the P 
value with the number of statistical tests performed (e.g., 
the vasodilator response to intra-arterial acetylcholine, 
which was analyzed in 4 separate models). If significant 
main effects or interactions were observed, the Tukey 
honestly significant difference post hoc procedure was 
used to detect all pairwise differences performed with 
multiple comparisons,28 and adjusted P values are re-
ported. A paired Student t test was used to estimate dif-
ferences in mRNA levels with ischemic preconditioning.
Two participants (1 man and 1 woman) failed to at-
tend their second visit but completed the initial visit. 
Consequently, the data presented for all measure-
ments before and after the hand-grip exercise include 
only 10 of the 12 participants. Furthermore, because 
of technical difficulties with sample preparation, data 
presented for changes in mRNA levels with ischemic 
preconditioning and data presented for platelet and 
platelet-free plasma levels include 11 of the 12 partici-
pants (clarified in figure labels). The influence of sex and 
timing of the visits were initially evaluated statistically 
with a linear mixed model approach; however, no effect 
of either variable on “time” was found (absence of sig-
nificant interaction). Data are presented as mean±SEM.
RESULTS
Effect of Ischemic Preconditioning on 
Local and Remote Microvascular Function
Baseline
Mean arterial blood pressure, blood flow, and vascular 
conductance in the femoral and brachial arteries were 
unaltered by ischemic preconditioning (Table S2).
Vascular conductance
=
arterial blood flow
(mean arterial blood pressure−mean venous blood pressure)
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Leg and Forearm Microvascular Endothelial Cell 
Responsiveness to Acetylcholine Infusion
In the leg, the vasodilator response to intra-arterial 
acetylcholine was increased (P<0.05) at post+5 and 
post+90 compared with pre following ischemic pre-
conditioning (Figure 2). In the forearm, no differences 
were detected in vasodilatory responsiveness to in-
tra-arterial acetylcholine after ischemic precondition-
ing. All changes in blood flow, vascular conductance, 
mean arterial blood pressure, and venous blood pres-
sure for both extremities are presented in Table S3.
Leg and Forearm Microvascular Smooth Muscle 
Cell Responsiveness to Epoprostenol and 
Sodium Nitroprusside Infusions
In the leg and forearm, no differences were detected 
in vasodilatory responsiveness to intra-arterial epo-
prostenol or sodium nitroprusside following ischemic 
preconditioning (Figure 2; Table S4). Baseline values 
and all changes in blood flow, vascular conduct-
ance, mean arterial blood pressure, and venous 
blood pressure for both extremities are presented in 
Tables S4 and S5.
Venous Plasma 6-keto PGF1α and 
Norepinephrine Levels Before and After 
Ischemic Preconditioning
Baseline
In the leg, no differences were detected in venous 
plasma 6-keto PGF1α or norepinephrine levels with is-
chemic preconditioning. In the forearm, venous plasma 
6-keto PGF1α levels were increased (P<0.05) at post+5 
compared with pre, whereas venous plasma norepi-
nephrine levels were increased (P<0.05) at post+5 and 
post+90 compared with pre following ischemic pre-
conditioning (Table S2).
Changes in Venous Plasma 6-keto PGF1α Levels 
With Acetylcholine Infusion
In the leg, the change in venous plasma 6-keto PGF1α 
levels from baseline to the highest dose of acetylcholine 
Figure 2. Leg and forearm vasodilator response to intra-arterial acetylcholine and epoprostenol before and after ischemic 
preconditioning of the forearm.
Absolute changes from baseline in leg and forearm vascular conductance with arterial infusion of acetylcholine (A and B) and 
epoprostenol (C and D). Data are presented as mean±SEM (n=12). *Significantly different from pre.
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was increased (P<0.05) at post+5 compared with 
pre following ischemic preconditioning, whereas no 
change was observed in the forearm venous plasma 
6-keto PGF1α level (Figure 3).
Effect of Ischemic Preconditioning on 
Serotonin, BDNF, and VEGF in Platelets 
and Platelet-Free Plasma
In platelets, no differences were detected in either ser-
otonin, BDNF, or VEGF with ischemic preconditioning. 
Platelet-free plasma levels of BDNF and VEGF were 
increased (P<0.05) at post arm compared with pre 
and post leg, whereas serotonin levels were unal-
tered with ischemic preconditioning (Figure 4).
Skeletal Muscle mRNA Levels Before and 
After Ischemic Preconditioning
Endothelial NO synthase, prostacyclin synthase, and cy-
clooxygenase 1 mRNA levels in skeletal muscle were sim-
ilar before and after ischemic preconditioning (Figure 5).
Figure 3. Changes in leg and forearm venous plasma 6-keto PGF1α levels with intra-arterial acetylcholine.
Absolute changes from baseline to the highest dose of acetylcholine in venous plasma levels of 6-keto PGF1α before and after 
ischemic preconditioning of the forearm (n=12) (A) and hand-grip exercise (n=10) (B). Data are presented as mean±SEM. *Significantly 
different from pre. 6-keto PGF1α, 6-keto prostaglandin F1α.
Figure 4. Platelet content and platelet-free plasma levels of serotonin, VEGF, and BDNF before and after ischemic 
preconditioning of the forearm.
Platelet content (A through C) and platelet-free plasma levels (D through F) of serotonin, VEGF, and BDNF. Data are presented as 
mean±SEM (n=11). *Significantly different from pre; #significantly different from post+5. BDNF, brain-derived neurotrophic factor; and 
VEGF, vascular endothelial growth factor.
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Effect of Hand-Grip Exercise on Local 
and Remote Microvascular Function
Baseline
Mean arterial blood pressure in the femoral and bra-
chial arteries remained unaltered by hand-grip exer-
cise. In the leg, blood flow and vascular conductance 
were similar after hand-grip exercise, whereas in the 
forearm blood flow and vascular conductance were 
increased (P<0.05) at post+5 compared with pre and 
post+90 (Table S2).
Leg and Forearm Microvascular Endothelial Cell 
Responsiveness to Acetylcholine Infusion
In the leg, no differences were detected in vaso-
dilatory responsiveness to intra-arterial acetylcho-
line with hand-grip exercise. In the forearm, the 
vasodilator response to intra-arterial acetylcholine 
was increased (P<0.05) at post+5 and post+90 
compared with pre following hand-grip exercise 
(Figure  6). All changes in blood flow, vascular 
conductance, mean arterial blood pressure, and 
venous blood pressure for both extremities are 
presented in Table S3.
Leg and Forearm Microvascular Smooth Muscle 
Cell Responsiveness to Epoprostenol and 
Sodium Nitroprusside Infusions
In the leg and forearm, no differences were detected in 
vasodilatory responsiveness to intra-arterial epopros-
tenol or sodium nitroprusside with hand-grip exercise 
(Figure 6; Table S4). Baseline values and all changes 
in blood flow, vascular conductance, mean arterial 
blood pressure, and venous blood pressure for both 
extremities are presented in Tables S4 and S5.
Venous Plasma 6-keto PGF1α and 
Norepinephrine Levels Before and After 
Hand-Grip Exercise
Baseline
In the leg and forearm, no differences were detected in 
venous plasma 6-keto PGF1α or norepinephrine levels 
with hand-grip exercise (Table S2).
Changes in Venous Plasma 6-keto PGF1α Levels 
With Acetylcholine Infusion
In the leg and forearm, no differences were detected 
in changes in venous plasma 6-keto PGF1α levels from 
baseline to the highest dose of acetylcholine with 
hand-grip exercise (Figure 3).
DISCUSSION
The principal finding of this study was that an acute 
bout of ischemic preconditioning performed on the 
arm induced a sustained improvement in micro-
vascular endothelial function in the leg, that is, a 
remote effect, as indicated by an enhanced vaso-
dilator response to arterial acetylcholine infusion. 
The enhanced acetylcholine induced response 
in leg vascular conductance was paralleled by a 
greater increase in venous plasma prostacyclin 
levels, suggesting that the increased sensitivity to 
acetylcholine was related to enhanced formation 
of prostacyclin. The enhancement in prostacyclin 
levels was in turn associated with transiently in-
creased platelet-free plasma levels of VEGF and 
BDNF, compounds known to stimulate endothelial 
prostacyclin formation. Our findings demonstrate, 
for the first time in humans, that ischemic precondi-
tioning leads to improved remote microvascular en-
dothelial function, an effect that may be related to 
increased prostacyclin production. Hand-grip exer-
cise did not significantly alter remote microvascular 
endothelial function. This finding indicates a differ-
ent mechanistic effect of exercise versus ischemic 
preconditioning and underlines the unique effect of 
ischemic preconditioning for promoting remote vas-
cular protection.
Effect of Ischemic Preconditioning on 
Remote Microvascular Function
Remote ischemic preconditioning was originally 
shown to prevent vascular damage associated with 
Figure 5. Skeletal muscle mRNA levels of eNOS, PGIS, 
and COX1 before and after ischemic preconditioning of the 
forearm.
mRNA levels of eNOS, PGIS, and COX1 in skeletal muscle 
homogenates from m. vastus lateralis. Data are presented as 
mean±SEM (n=11). COX1, cyclooxygenase 1; eNOS, endothelial 
nitric oxide synthase; and PGIS, prostacyclin synthase.
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prolonged tissue ischemia,4 indicating that the pro-
cedure may induce a systemic stimulus leading to 
functional adaptations in vascular endothelium. We 
demonstrate that acute exposure to ischemic pre-
conditioning of the arm enhances the acetylcholine-
induced change in leg vascular conductance. The 
effect was present within 5  minutes after the pro-
cedure and persisted for at least 90  minutes. The 
enhanced vasodilator response was not paralleled 
by changes in smooth muscle cell sensitivity, as in-
dicated by an unaltered responsiveness to the NO 
donor, sodium nitroprusside, and the prostacyclin 
analog, epoprostenol, emphasizing that the improve-
ment was localized to the endothelium. In support 
of an improvement at the endothelial level, the ace-
tylcholine-induced increase in plasma prostacyclin 
levels was higher in the leg after ischemic precon-
ditioning, suggesting that the procedure potenti-
ated prostacyclin production. This finding is in line 
with the proposition that prostacyclin is important 
for vascular protection induced by remote ischemic 
preconditioning22,23 and that targeting prostacyclin 
formation may play a central role in treating patients 
with endothelial dysfunction.29
Increased prostacyclin production by ischemic 
preconditioning could be explained by an enhanced 
receptor sensitivity to acetylcholine, a higher sub-
strate availability or, alternatively, increased enzyme 
activity in the prostacyclin system. In the current 
study, we examined local and systemic alterations in 
3 compounds known to enhance endothelial prosta-
glandin formation: serotonin, BDNF, and VEGF.16,30–33 
These compounds can be transported both in plate-
lets and in plasma, and therefore these fractions 
were analyzed separately. The purpose was to as-
sess whether the remote effect of the ischemic pre-
conditioning intervention was associated with an 
increase in these compounds either by platelets or 
in platelet-free plasma. We observed increased lev-
els of BDNF and VEGF in platelet-free plasma after 
ischemic preconditioning, indicating that these com-
pounds could have been transported in plasma to the 
Figure 6. Leg and forearm vasodilator response to intra-arterial acetylcholine and epoprostenol before and after hand-grip 
exercise.
Absolute changes from baseline in leg and forearm vascular conductance with arterial infusion of acetylcholine (A and B) and 
epoprostenol (C and D). Data are presented as mean±SEM (n=10). *Significantly different from pre; #significantly different from post+5.
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remote vasculature and influenced the prostacyclin 
production, although further evidence for this possi-
bility is clearly needed. Transport of BDNF and VEGF 
by platelets could not be verified as the level of these 
compounds in the platelet fraction remained unal-
tered after the ischemic preconditioning. Combined, 
our findings suggest that ischemic preconditioning 
leads to an improvement in remote microvascular en-
dothelial function through humoral signaling, leading 
to increased prostacyclin production.
Sustained Effect of Remote Ischemic 
Preconditioning
Previous studies have documented a sustained ef-
fect of ischemic preconditioning: a second window, 
lasting for up to 48 hours after the procedure.34 Such 
a sustained effect could be attributed to alterations 
at the transcriptional level. We therefore determined 
the mRNA levels of prostacyclin synthase, cyclooxy-
genase 1, and endothelial NO synthase in skeletal 
muscle biopsies obtained before and 2.5 hours after 
ischemic preconditioning. A potential increase in 
mRNA levels of proteins related to the formation of 
vasoactive compounds is also of interest in relation 
to the observed beneficial effect of a period of daily 
treatment with ischemic preconditioning on vascular 
function.35–37 No significant alterations in mRNA lev-
els were, however, detected for either of the vasodi-
lator enzymes, and the present study was not able 
to confirm the hypothesis that the sustained effect 
of ischemic preconditioning would be attributed to 
the upregulation of these vasodilator enzymes. It is, 
however, worth noting that endothelial NO synthase 
mRNA was numerically higher after ischemic pre-
conditioning in 9 of the 11 participants, which may 
indicate that ischemic preconditioning can lead to 
upregulation of endothelial NO synthase.
It should also be clarified that our finding does not 
exclude that an increased mRNA expression could 
occur at a later time than measured here or that other 
vasoactive proteins could be influenced.
Effect of Ischemic Preconditioning on 
Local Microvascular Function
Ischemic preconditioning was not found to influence 
the vasodilator response to acetylcholine locally in the 
forearm, a finding that may have been related to an 
opposing negative effect of the procedure attributed 
to local ischemia. Ischemia reperfusion can lead to an 
increased formation of reactive oxygen species in skel-
etal muscle,38 which readily remove NO and interfere 
with prostacyclin formation.39,40 Thus, the availability of 
these vasoactive compounds may have been reduced 
locally in the arm, counteracting the enhanced vasodi-
latory capacity observed in the leg.
Effect of Exercise Preconditioning on 
Local and Remote Microvascular Function
We examined the functional effect of exercise pre-
conditioning to assess whether exercise could also 
induce a remote effect. Previous studies have re-
ported that exercise can induce a preconditioning ef-
fect similar to that of ischemic preconditioning at the 
macrovascular level,8 however, it is unclear whether 
exercise improves remote microvascular vasodilatory 
responsiveness. The remote microvascular response 
to acetylcholine infusion was not detectably altered by 
hand-grip exercise, whereas an improved response 
was found locally in the arm. Smooth muscle sensitiv-
ity to NO and prostacyclin was not significantly altered 
locally in the arm, suggesting that primarily endothe-
lial function was improved locally by the exercise. The 
improved vasodilator response to acetylcholine in the 
arm was not paralleled by a greater change in plasma 
prostacyclin levels during arterial acetylcholine infu-
sion. This finding suggests that the mechanism medi-
ating vascular changes with exercise may be different 
from that of ischemic preconditioning.
The lack of effect of hand-grip exercise on remote 
microvascular responsiveness and prostacyclin for-
mation indicates that the previously observed effect 
of exercise preconditioning on remote endothelial 
injury8 is not likely caused by changes in microvas-
cular endothelial function. The explanation for the 
difference between exercise and ischemia can only 
be speculated on, but it appears plausible that the 
observed remote signaling specifically is depen-
dent on an ischemic insult that cannot be induced 
by dynamic hand-grip exercise. Overall, our current 
observations suggest that the mechanism by which 
ischemic preconditioning influences vascular func-
tion is different from that of exercise. The precise 
mechanism underlying the local effect of exercise re-
mains to be elucidated.
Study Limitations
To assess the acute effect of remote ischemic pre-
conditioning on microvascular function, infusions of 
the vasoactive compounds were repeated 3 times 
during the experimental day. The sequence of drugs 
was kept the same in the protocols to keep the time 
after the interventions constant. This procedure 
raises the possibility that the observed changes may 
have been influenced by the prior infusion. However, 
it is our experience from many years of conducting 
infusion with these same drugs that the short-term 
infusions used do not impact the vasodilatory re-
sponse of other subsequent drugs. Moreover, the 
lack of influence of previously infused drugs was 
verified by the clear difference in remote and local 
vasodilator responses on the 2 experimental days 
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involving ischemic preconditioning and hand-grip ex-
ercise, respectively.
The improved sensitivity to acetylcholine after 
ischemic preconditioning could, in addition to in-
creased prostacyclin production, also have been 
due to an enhanced formation of NO. As NO is short 
lived, venous plasma levels can only be indirectly as-
sessed as the stable metabolites nitrite and nitrate. 
However, because nitrite and nitrate are rather insen-
sitive markers, limited changes in formation would 
not have been possible to detect in plasma. As a re-
sult, we cannot exclude the possibility that a poten-
tiation of NO formation contributed to the improved 
vasodilator response to acetylcholine after ischemic 
preconditioning. It should also be mentioned that 
signaling proteins may be carried by microvesicles 
or cells in the blood41; however, this was not studied 
in the current investigation and thus their role cannot 
be ruled out.
Conclusions
The present study demonstrates for the first time 
in humans that ischemic preconditioning of the 
forearm leads to an improved vasodilator response 
to arterial acetylcholine infusion in the leg and to 
an associated increase in formation of prostacy-
clin. This finding indicates that the remote effect 
of ischemic preconditioning is related to a poten-
tiation of the prostacyclin system. Furthermore, in 
contrast to our hypothesis, the study did not de-
tect an improved remote microvascular function in 
response to preconditioning by hand-grip exercise. 
Collectively, these findings suggest that ischemic 
preconditioning may be an effective new treatment 
strategy in conditions associated with microvascu-
lar endothelial dysfunction.
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 Table S1. Participant characteristics. 
 
 
Variable 
Age (years) 23 ± 1 
Height (cm) 175 ± 3 
Body mass (kg) 71 ± 2 
VO2 max (ml O2 min-1) 3263 ± 218 
VO2 max (ml O2 min-1  kg-1) 48 ± 2 
Systolic blood pressure (mmHg) 112 ± 3 
Diastolic blood pressure (mmHg) 67 ± 2 
Hemoglobin (mmol L-1) 8.6 ± 0.2 
Thrombocytes (109 L-1) 277 ± 16 
Glycated hemoglobin (mmol L-1) 5.3 ± 0.1 
Total cholesterol (mmol L-1) 4.2 ± 0.4page s 
High-density lipoprotein (mmol L-1) 1.4 ± 0.2 
Low-density lipoprotein (mmol L-1) 2.6 ± 0.3 
Triglycerides (mmol L-1) 1.0 ± 0.1 
Female sex hormones 
Ischemic 
preconditioning (n=5) 
Hand-grip exercise 
(n=4) 
Estrogen (nmol L-1) 0.17 ± 0.03 0.22 ± 0.13 
Progesterone (nmol L-1) 0.60 ± 0.00 0.63 ± 0.03 
VO2 max, maximal oxygen uptake. Data are presented as mean ± SEM (n=12). 
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Table S2. Baseline hemodynamics and venous plasma 6-keto prostaglandin F 1α and norepinephrine levels. 
Leg Ischemic preconditioning (n=12) 
ANOVA P 
values 
Hand-grip exercise (n=10) 
ANOVA P 
values 
Variable Pre Post+5 Post+90 Time Pre Post+5 Post+90 Time 
Leg blood flow (ml 
min-1) 
276 ± 42 306 ± 34 349 ± 47 P=0.8704 330 ± 43 321 ± 36 351 ± 40 P=1.0 
Leg vascular 
conductance (ml min- 
1 mmHg-1) 
 
3.6 ± 0.5 
 
4.0 ± 0.4 
 
4.4 ± 0.6 
 
P=1.0 
 
4.4 ± 0.5 
 
4.1 ± 0.4 
 
4.6 ± 0.5 
 
P=1.0 
Mean arterial 
pressure (mmHg) 
81 ± 2 80 ± 2 81 ± 2 P=1.0 79 ± 2 80 ± 2 79 ± 2 P=0.9532 
Venous pressure 
(mmHg) 
3 ± 1 2 ± 0 * 2 ± 0 * P<0.0001 4 ± 1 3 ± 0 3 ± 1 P=1.0 
Heart rate (bpm) 63 ± 3 63 ± 3 61 ± 2 P=1.0 63 ± 3 63 ± 3 62 ± 4 P=1.0 
Venous 
norepinephrine (nmol 
l-1) 
 
0.9 ± 0.1 
 
1.1 ± 0.2 
 
1.0 ± 0.1 
 
P=1.0 
 
0.9 ± 0.1 
 
0.9 ± 0.1 
 
0.9 ± 0.1 
 
P=1.0 
Venous 6-keto PGF1α 
(pg ml-1) 
61 ± 4 59 ± 7 - P=1.0 75 ± 4 72 ± 6 - P=1.0 
Forearm Ischemic preconditioning (n=12) 
ANOVA P 
values 
Hand-grip exercise (n=10) 
ANOVA P 
values 
Variable Pre Post+5 Post+90 Time Pre Post+5 Post+90 Time 
Forearm blood flow 
(ml min-1) 
94 ± 18 60 ± 8 81 ± 12 P=0.0762 79 ± 15 146 ± 17 * 92 ± 13 # P<0.0001 
Forearm vascular 
conductance (ml min- 
1 mmHg-1) 
 
1.3 ± 0.3 
 
0.8 ± 0.1 
 
1.0 ± 0.2 
 
P=0.0947 
 
1.0 ± 0.2 
 
1.9 ± 0.2 * 
 
1.2 ± 0.2 # 
P<0.0001 
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 Mean arterial 
pressure (mmHg) 
80 ± 2 79 ± 2 80 ± 2 P=0.6088 78 ± 2 78 ± 2 78 ± 2 P=1.0 
Venous pressure 
(mmHg) 
3 ± 0 2 ± 1 2 ± 0 P=0.2116 4 ± 1 3 ± 0 2 ± 1 * P=0.0030 
Venous 
norepinephrine 
(nmol l-1) 
 
1.0 ± 0.1 
 
1.4 ± 0.1 * 
 
1.3 ± 0.1 * 
 
P=0.0040 
 
1.0 ± 0.1 
 
1.1 ± 0.2 
 
1.0 ± 0.1 
 
P=1.0 
Venous 6-keto PGF1α 
(pg ml-1) 
56 ± 5 76 ± 10 * - P=0.0084 77 ± 8 60 ± 5 - P=0.2277 
 
Data are presented as mean ± SEM. * denotes post-hoc significantly different from Pre within intervention; # denotes post-hoc significantly 
different from Post+5 within intervention. 
D
ow
nloaded from
 http://ahajournals.org by on August 18, 2020
  
Table S3. Absolute changes in hemodynamics with intra-arterial infusion of acetylcholine. 
Leg Ischemic preconditioning (n=12) ANOVA P values Hand-grip exercise (n=10) ANOVA P values 
Variable Pre Post+5 Post+90 Time 
Time x 
Dose 
Pre Post+5 Post+90 Time 
Time x 
Dose 
Δ LBF (Ach; 10 
µg min-1 L-1) 
914 ± 121 
1206 ± 
132 * 
1152 ± 
185 * 
 
 
P=0.0163 
 
 
P=1.0 
1259 ± 
184 
1118 ± 
199 
1216 ± 
200 
 
 
P=1.0 
 
 
P=1.0 
Δ LBF (Ach; 25 
µg min-1 L-1) 
1214 ± 
168 
1709 ± 
178 * 
1513 ± 
201 * 
1495 ± 
230 
1440 ± 
253 
1551 ± 
243 
Δ MAP (Ach; 
10 µg min-1 L-1) 
-1.9 ± 0.5 
-3.7 ± 0.8 
* 
-3.8 ± 1.0 
* 
 
 
P=0.0027 
 
 
P=1.0 
-3.6 ± 0.9 -4.4 ± 1.1 -3.5 ± 0.9 
 
 
P=0.6056 
 
 
P=1.0 
Δ MAP (Ach; 
25 µg min-1 L-1) 
-2.0 ± 0.6 
-3.6 ± 0.7 
* 
-5.0 ± 1.2 
* 
-2.2 ± 1.0 -4.3 ± 1.4 -2.8 ± 1.0 
Δ VP (Ach; 10 
µg min-1 L-1) 
-0.2 ± 0.4 0.1 ± 0.1 0.1 ± 0.3 
 
 
P=0.2930 
 
 
P=1.0 
0.1 ± 0.2 0.0 ± 0.3 -0.2 ± 0.2 
 
 
P=1.0 
 
 
P=1.0 
Δ VP (Ach; 25 
µg min-1 L-1) 
-0.4 ± 0.4 0.4 ± 0.3 0.0 ± 0.3 -0.1 ± 0.3 -0.3 ± 0.4 -0.2 ± 0.3 
Forearm Ischemic preconditioning (n=12) ANOVA P values Hand-grip exercise (n=10) ANOVA P values 
Variable Pre Post+5 Post+90 Time 
Time x 
Dose 
Pre Post+5 Post+90 Time 
Time x 
Dose 
Δ FBF (Ach; 10 
µg min-1 L-1) 
77 ± 14 68 ± 12 96 ± 13 
 
 
P=0.6141 
 
 
P=1.0 
46 ± 12 
118 ± 19 
* 
91 ± 19 * 
 
 
P<0.0001 
 
 
P=1.0 
Δ FBF (Ach; 25 
µg min-1 L-1) 
99 ± 19 127 ± 18 134 ± 24 98 ± 14 
185 ± 19 
* 
157 ± 27 
* 
Δ MAP (Ach; 
10 µg min-1 L-1) 
-2.8 ± 0.7 -3.4 ± 0.9 -4.3 ± 0.9 
 
 
P=0.0853 
 
 
P=1.0 
-3.7 ± 0.6 -4.6 ± 0.8 -3.5 ± 0.9 
 
 
P=0.7396 
 
 
P=1.0 
Δ MAP (Ach; 
25 µg min-1 L-1) 
-3.7 ± 0.5 -4.1 ± 0.9 -5.9 ± 0.9 -3.3 ± 0.8 -5.2 ± 1.1 -3.7 ± 1.1 
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 Δ VP (Ach; 10 
µg min-1 L-1) 
0.5 ± 0.3 0.2 ± 0.3 0.1 ± 0.4 
0.2 ± 0.2 0.6 ± 0.2 
* 
0.5 ± 0.3 
* Δ VP (Ach; 25 
µg min-1 L-1) 
0.5 ± 0.3 0.7 ± 0.3 0.3 ± 0.4 
0.4 ± 0.3 1.0 ± 0.2 
* 
1.0 ± 0.4 
*  
LBF, leg blood flow; FBF, forearm blood flow; MAP, mean arterial pressure; VP, venous pressure; Ach, acetylcholine. Data are presented as 
mean ± SEM. * denotes post-hoc overall significantly different from Pre within intervention. 
D
ow
nloaded from
 http://ahajournals.org by on August 18, 2020
  
Table S4. Absolute changes in hemodynamics with intra-arterial infusion of sodium nitroprusside. 
Leg Ischemic preconditioning (n=12) ANOVA P values Hand-grip exercise (n=10) ANOVA P values 
Variable Pre Post+5 Post+90 Time 
Time x 
Dose 
Pre Post+5 Post+90 Time 
Time x 
Dose 
Baseline LVC 
(ml min-1 
mmHg-1) 
 
3.2 ± 0.4 
 
3.6 ± 0.4 
4.5 ± 0.5 
*# 
 
P<0.0001 
 
- 
 
4.3 ± 0.5 
 
3.3 ± 0.4 
 
3.9 ± 0.4 
 
P=0.2958 
 
- 
Δ LVC (SNP; 3 
µg min-1 L-1) 
9.6 ± 1.1 10.6 ± 1.3 9.3 ± 1.3 P=0.4828 - 
11.9 ± 
1.0 
12.1 ± 
1.4 
12.3 ± 
1.9 
P=1.0 - 
Baseline LBF 
(ml min-1) 
252 ± 28 285 ± 36 
362 ± 38 
*# 
P<0.0001 - 321 ± 38 248 ± 27 301 ± 36 P=0.3524 - 
Δ LBF (SNP; 3 
µg min-1 L-1) 
651 ± 77 714 ± 83 626 ± 85 P=0.8164 - 740 ± 60 810 ± 98 
814 ± 
124 
P=1.0 - 
Baseline MAP 
(mmHg) 
81.7 ± 2.1 80.2 ± 1.9 81.3 ± 2.0 P=0.9896 - 
78.7 ± 
3.2 
78.7 ± 
2.8 
79.9 ± 
2.1 
P=1.0 - 
Δ MAP (SNP; 3 
µg min-1 L-1) 
-7.8 ± 0.7 -7.8 ± 0.8 -7.5 ± 0.9 P=1.0 - -9.0 ± 1.3 -7.3 ± 0.6 -7.4 ± 1.3 P=1.0 - 
Baseline VP 
(mmHg) 
2.8 ± 0.4 
1.5 ± 0.4 
* 
1.6 ± 0.5 
* 
P<0.0001 - 3.9 ± 0.7 
2.4 ± 0.4 
* 
2.7 ± 0.5 
* 
P=0.0035 - 
Δ VP (SNP; 3 
µg min-1 L-1) 
-0.3 ± 0.3 0.0 ± 0.3 0.1 ± 0.3 P=1.0 - -0.5 ± 0.5 -0.2 ± 0.2 -0.1 ± 0.2 P=1.0 - 
Forearm IPC (n=12) ANOVA P values Hand-grip exercise (n=10) ANOVA P values 
Variable Pre Post+5 Post+90 Time 
Time x 
Dose 
Pre Post+5 Post+90 Time 
Time x 
Dose 
Baseline FVC 
(ml min-1 
mmHg-1) 
 
1.3 ± 0.2 
 
1.0 ± 0.1 
 
1.0 ± 0.1 
 
P=0.7328 
 
- 
 
1.3 ± 0.3 
 
1.2 ± 0.1 
 
1.1 ± 0.2 
 
P=1.0 
 
- 
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 Δ FVC (SNP; 
3 
µg min-1 kg-
1) 
1.7 ± 0.3 1.7 ± 0.3 1.8 ± 0.3 P=1.0 - 1.6 ± 0.3 2.0 ± 0.2 1.6 ± 0.1 P=1.0 - 
Baseline FBF 
(ml min-1) 
96 ± 17 77 ± 10 82 ± 9 P=0.7612 - 94 ± 20 90 ± 14 87 ± 16 P=1.0 - 
Δ FBF (SNP; 
3 
µg min-1 L-
1) 
102 ± 18 107 ± 19 116 ± 18 P=1.0 - 90 ± 16 120 ± 16 99 ± 7 P=0.8980 - 
Baseline 
MAP 
(mmHg) 
80.5 ± 2.1 79.5 ± 1.8 80.5 ± 2.0 P=1.0 - 78.0 ± 3.2 78.0 ± 2.7 78.8 ± 1.9 P=1.0 - 
Δ MAP (SNP; 
3 
µg min-1 L-
1) 
-9.6 ± 0.7 -9.5 ± 0.8 -9.4 ± 1.0 P=1.0 - -10.7 ± 
1.2 
-8.9 ± 0.6 -8.5 ± 1.4 P=1.0 - 
Baseline VP 
(mmHg) 
2.9 ± 0.5 2.0 ± 0.6 
* 
1.5 ± 0.5 
* 
P=0.0024 - 3.6 ± 0.6 2.5 ± 0.6 
* 
2.2 ± 0.6 
* 
P<0.0001 - 
Δ VP (SNP; 3 
µg min-1 L-
1) 
-0.6 ± 0.2 0.1 ± 0.2 
* 
0.5 ± 0.1 
* 
P<0.0001 - -0.5 ± 0.3 0.0 ± 0.2 0.0 ± 0.3 P=0.1502 - 
 
LVC, leg vascular conductance; FVC, forearm vascular conductance; LBF, leg blood flow; FBF, forearm blood flow; MAP, mean arterial 
pressure; VP, venous pressure; SNP, sodium nitroprusside. Data are presented as mean ± SEM. * denotes post-hoc significantly different 
from Pre within intervention; # denotes post-hoc significantly different from Post+5 within intervention. 
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 Table S5. Absolute changes in hemodynamics with intra-arterial infusion of epoprostenol. 
Leg Ischemic preconditioning (n=12) ANOVA P values Hand-grip exercise (n=10) ANOVA P values 
Variable Pre Post+5 Post+90 Time 
Time x 
Dose 
Pre Post+5 Post+90 Time 
Time x 
Dose 
Baseline LVC 
(ml min-1 
mmHg-1) 
 
3.2 ± 0.4 
 
3.9 ± 0.5 
4.9 ± 0.8 
* 
 
P=0.0136 
 
- 
 
4.4 ± 0.5 
 
3.9 ± 0.5 
 
4.3 ± 0.3 
 
P=1.0 
 
- 
Baseline LBF 
(ml min-1) 
247 ± 32 310 ± 40 
400 ± 73 
* 
P=0.0155 - 326 ± 38 290 ± 36 325 ± 29 P=1.0 - 
Δ LBF (Epo; 25 
µg min-1 L-1) 
243 ± 39 255 ± 50 187 ± 47 
 
 
P=1.0 
 
 
P=1.0 
286 ± 44 268 ± 58 216 ± 42 
 
 
P=1.0 
 
 
P=1.0 
Δ LBF (Epo; 50 
µg min-1 L-1) 
352 ± 50 339 ± 53 334 ± 68 389 ± 45 416 ± 60 365 ± 61 
Baseline MAP 
(mmHg) 
81.3 ± 2.1 81.2 ± 1.8 82.1 ± 1.7 P=1.0 - 
78.2 ± 
2.5 
77.9 ± 
2.3 
78.9 ± 
2.0 
P=1.0 - 
Δ MAP (Epo; 
25 µg min-1 L-1) 
-2.3 ± 0.9 -4.2 ± 0.9 -3.1 ± 0.7 
 
 
P=0.3572 
 
 
P=1.0 
-1.6 ± 0.9 0.3 ± 1.3 -2.0 ± 0.7 
 
 
P=0.5364 
 
 
P=1.0 
Δ MAP (Epo; 
50 µg min-1 L-1) 
-4.5 ± 1.1 -5.6 ± 0.9 -4.1 ± 0.9 -3.6 ± 1.2 -2.5 ± 1.4 -2.5 ± 1.0 
Baseline VP 
(mmHg) 
3.4 ± 0.4 
2.1 ± 0.4 
* 
1.8 ± 0.4 
* 
P<0.0001 - 4.4 ± 0.8 3.0 ± 0.5 3.2 ± 0.7 P=0.1879 - 
Δ VP (Epo; 25 
µg min-1 L-1) 
-0.4 ± 0.2 -0.1 ± 0.1 0.0 ± 0.2 
 
 
P=0.1600 
 
 
P=1.0 
-0.2 ± 0.3 
-0.4 ± 0.2 
* 
0.0 ± 0.2 
# 
 
 
P=0.0347 
 
 
P=1.0 
Δ VP (Epo; 50 
µg min-1 L-1) 
-0.2 ± 0.2 0.0 ± 0.2 0.2 ± 0.2 0.1 ± 0.3 
-0.5 ± 0.2 
* 
0.0 ± 0.2 
# 
Forearm IPC (n=12) ANOVA P values Hand-grip exercise (n=10) ANOVA P values 
Variable Pre Post+5 Post+90 Time 
Time x 
Dose 
Pre Post+5 Post+90 Time 
Time x 
Dose 
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 Baseline FVC 
(ml min-1 
mmHg-1) 
 
1.1 ± 0.2 
 
1.0 ± 0.1 
 
1.0 ± 0.1 
 
P=1.0 
 
- 
 
1.2 ± 0.2 
 
1.2 ± 0.2 
 
0.9 ± 0.2 
 
P=1.0 
 
- 
Baseline FBF 
(ml min-1) 
83 ± 14 78 ± 11 79 ± 9 P=1.0 - 88 ± 16 91 ± 15 70 ± 12 P=1.0 - 
Δ FBF (Epo; 25 
µg min-1 L-1) 
70 ± 10 72 ± 6 58 ± 8 
 
 
P=0.5784 
 
 
P=1.0 
73 ± 14 84 ± 10 78 ± 13 
 
 
P=1.0 
 
 
P=1.0 
Δ FBF (Epo; 50 
µg min-1 L-1) 
106 ± 12 103 ± 9 96 ± 9 109 ± 16 116 ± 16 113 ± 13 
Baseline MAP 
(mmHg) 
80.5 ± 2.1 80.5 ± 1.8 81.6 ± 1.6 P=1.0 - 
77.6 ± 
2.4 
77.3 ± 
2.2 
78.6 ± 
1.9 
P=1.0 - 
Δ MAP (Epo; 
25 µg min-1 L-1) 
-4.0 ± 1.1 -6.0 ± 0.9 -4.6 ± 0.8 
 
 
P=0.1672 
 
 
P=1.0 
-3.2 ± 0.9 -1.3 ± 1.4 -3.6 ± 0.7 
 
 
P=0.7300 
 
 
P=1.0 
Δ MAP (Epo; 
50 µg min-1 L-1) 
-7.4 ± 1.1 -8.7 ± 0.9 -6.8 ± 0.9 -6.4 ± 0.9 -5.2 ± 1.5 -5.2 ± 1.1 
Baseline VP 
(mmHg) 
3.3 ± 0.4 2.2 ± 0.5 2.0 ± 0.6 P=0.1100 - 3.1 ± 0.6 2.7 ± 0.6 2.2 ± 0.7 P=0.0757 - 
Δ VP (Epo; 25 
µg min-1 L-1) 
0.0 ± 0.5 0.3 ± 0.2 0.1 ± 0.2 
 
 
P=0.8820 
 
 
P=1.0 
0.6 ± 0.3 0.3 ± 0.1 0.4 ± 0.3 
 
 
P=0.9056 
 
 
P=1.0 
Δ VP (Epo; 50 
µg min-1 L-1) 
0.0 ± 0.5 0.6 ± 0.2 0.3 ± 0.2 0.7 ± 0.4 0.3 ± 0.3 0.8 ± 0.4 
 
LVC, leg vascular conductance; FVC, forearm vascular conductance; LBF, leg blood flow; FBF, forearm blood flow; MAP, mean arterial 
pressure; VP, venous pressure; Epo, epoprostenol. Data are presented as mean ± SEM. * denotes post-hoc overall significantly different 
from Pre within intervention; # denotes post-hoc overall significantly different from Post+5 within intervention. 
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